AXL-TBK1 driven AKT3 activation promotes metastasis 

Emily N Arner et al.

Sci Signal. 2024 Dec 17;17(867):eado6057. doi: 10.1126/scisignal.ado6057. Epub 2024 Dec 17.

Published on December 17, 2024

Abstract

ABSTRACT

The receptor tyrosine kinase AXL promotes tumor progression, metastasis, and therapy resistance through the induction of epithelial-mesenchymal transition (EMT). Here, we found that activation of AXL resulted in the phosphorylation of TANK-binding kinase 1 (TBK1) and the downstream activation of AKT3 and Snail, a transcription factor critical for EMT. Mechanistically, we showed that TBK1 directly bound to and phosphorylated AKT3 in a manner dependent on the multiprotein complex mTORC1. Upon activation, AKT3 interacted with and promoted the nuclear accumulation of Snail, which led to increased EMT as assessed by marker abundance. In human pancreatic ductal adenocarcinoma tissue, nuclear AKT3 colocalized with Snail and correlated with worse clinical outcomes. Primary mouse pancreatic cancer cells deficient in AKT3 showed reduced metastatic spread in vivo, suggesting selective AKT3 inhibition as a potential therapeutic avenue for targeting EMT in aggressive cancers.

PMID:39689180 | DOI:10.1126/scisignal.ado6057

 Read More

← Back to Publications
Sam van Puyenbroeck et al.Nat Methods. 2026 Nov 3. doi: 10.1038/s41592-026-03301-9. Online ahead of print.
Xiaofei Chen et al.J Orthop Translat. 2026 Oct 25;61:101241. doi: 10.1016/j.jot.2026.101241. eCollection 2026 Nov.
Saeka Shimochi et al.Pharmaceuticals (Basel). 2026 Oct 10;19(10):1610. doi: 10.3390/ph19101610.
Kim Kreuze et al.Res Sq [Preprint]. 2026 Oct 5:rs.3.rs-11232673. doi: 10.21203/rs.3.rs-11232673/v1.
Prince Dadson et al.Int J Obes (Lond). 2026 Oct 16. doi: 10.1038/s41366-026-02243-8. Online ahead of print.